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One of the recent targets is histone deacetylase (HDAC) which provide a very promising new approach for anticancer 
drugs, which may combine clinical efficacy with relatively mild toxicological side effects. Modification of histone 
acetylation level, promoted by histone acetylase (HAT) and HDAC enzyme, has been recognize to play an important role in 
epigenetic modulation of gene expression, so HDAC inhibitors are considered a new class of anticancer agents. A new series 
of hydroxamic and carboxylic acid analogues based on the 1,3,4-thiadiazole scaffold has been designed and synthesized 
with the aim of exploring its potential as new antitumor agents. Biological results have revealed that the structural 
modifications proposed significantly affected inhibitory potency as well as selectivity for HDAC inhibitors. Most target 
compounds are significantly more active, specifically 5a, 5b, 5e with IC50 values in the low micromolar or, the most active 
compounds in the series. Selected compounds have been tested on the viability of MDA-MB-231 (breast cancer cell) and 
K562 (chronic myelogenous leukemia cell), A549 (human lung cancer), PC3 (Prostate cancer cell lines) using MTT assay. 
Docking simulations suggested that the most active compounds can recognize the binding site (PDB Code 1w22 reference 
compound) using a similar interactions network. These results have allowed us to rationalize the observed structure–activity 
relationships. 
Keywords: Hydroxamic acid derivatives, carboxylic acid derivatives, anticancer agents, 1,3,4-thiadiazoles,computational study 
Histone acetylase and histone deacetylase two classes 
of enzyme work in opposing direction either by the 
transfer of acetyl group from acetyl Co A with the 
help of histoneacetylase (HATs) or removing  
acetyl group with histone deacetylase (HDACs)  
from lysine residue of histone tails1, 2 (Figure 1). 
Disturbance of Histone acetylasetransferase (HAT) 
and Histone deacetylase (HDACs) activities has been 
connected with the increase of a varied range of 
human cancers. Histone deacetylase (HDACs) 
inhibitors cause o increase of the acetylated level of 
histones, which in turn stimulate the re-expression of 
silenced controlling genes in cancer cells and inverse 
the malignant phenotype. Outstanding to this 
influence, Histone deacetylase (HDACs) inhibitors 
have recently emerged as potential cancer therapeutic 
agents3, 4. 
There are four classes of HDAC on their sequence 
homology to saccharomyces cerevisiae HDACs5, 6. 
Eighteen distinct human HDACs are grouped in this 
four main category.The HDAC family is divided into 
Zn dependent (Class I and Class II) and NAD –
Dependent (Class III) enzymes. The Zn-dependent 
enzymes have been the focus of intense research, 
while the Sir2 family recently implicated in 
acetylation and regulation of key cell cycle proteins 
such as p53.Till date, eleven HDAC family members 
in classes I and II are characterized. i.e. HDACs 
1,2,3,8 are class 1 and HDACs 4-7,9,10 are class II, a 
grouping based on the sequence similarity. The most 
recent identified member of HDAC family is HDAC 
11 comprising in Class IV. ClassI family are 
homologous to yeast RPD-3 (reduced potassium 
dependency-3). They share a compact structure.  
They are predominantly nuclear proteins and 
ubiquitously expressed in most tissues and cell lines. 
Class II are homologous to yeast HDA-1-protien 
 
 
Figure 1 — Structural Requirement of Vorinostat 




(Histone deacetylase-1). It can be subdivided into two 
subclasses. Class IIa (HDAC 4,5,7,9) have one 
catalytic domain and long amino terminal adapter 
domain. Class II b (HDAC 6, HDAC 10) have two 
catalytic domain. Class II family HDACs are mainly 
confined in the cytoplasm, however depending upon 
the phosphorylation status they are split between the 
cytoplasm and nucleus. Class III inhibitors are also 
known as sirtuins as they comprise of seven members 
and they share sequence homology with yeast silent 
information regulator-2 (Sir-2) protein. They do not 
contain zinc and their activity require nicotinamide 
adenine dinucleotide (NAD+). Sirtuins (SIRTs) are 
found in three important cellular compartments: 
nucleus, cytoplasm and mitochondrion. Phylogenetically 
SIRTs are distributed into four classes (SIRT1,SIRT2 
and SIRT3 belong to class1,SIRT4 to class-II, SIRT5 
to Class III, and SIRT6 and SIRT7 to class IV). 
HDAC 11 has conserved residues in its catalytic 
center that are shared by both class I and Class II 
deacetylase and placed in Class IV7, 8. 
HDAC inhibitors of the hydroxamic class have 
common structural characteristics, (i) Capping group 
(surface recognition), that binds the protein and 
responsible for specificity, (ii) A straight chain alkyl, 
vinyl, or aryl linker that connect the ZBM and capping 
group and must fit in to the narrow hydrophobic group, 
(iii) Zinc binding moiety (ZBM) in catalytic pocket and 
give enzyme inhibitory activity9. 
In prototypical HDAC inhibitor, the capping group 
is solvent exposed and interacts with the amino acids 
near the entrance of the active site. The metal binding 
group resides in the protein interior and complexes 
the metal ion involved in catalysis. The incorporation 
of substituent on the linker adjacent to the metal 
binding moiety has a variable influence on inhibitory 
activity. 
HDAC enzyme remove the acetyl group from 
histone using a charge-relay mechanism consisting of 
two adjacent histidine residue and one tyrosine 
residue, and crucial for this charge-relay Zn2+ ion, 
which bind deep in the pocket of the enzyme. 
Novel HDAC inhibitors have been generated by 
modification on ZBM, linker and capping group.  
The catalytic core comprises a Zn2+ ion coordinated 
by two histidine residues and an aspartate, two his-asp 
dyed and a tyrosine residue. 
 
Results and Discussion 
HDAC inhibition activity of the 1,3,4-thiadiazole 
based hydroxamates and carboxylates (Scheme I) 
were assessed by the Color de Lys assay and the 
results are tabulated as IC50 values in Table I. 
According to the data in Table I, the substitution in 
1,3,4-thiadiazole(cap group) and the terminal 
hydroxamate and carboxylate group (Zinc binding 
group) play a role in potency. For example, 
compounds with the hydroxamic acid substitution are 
found to exhibit good activity micromolar level while 
carboxylic acid substitution proves to have less 
activity. In general, the substitutions in 1,3,4-
thiadiazole ring have an profound effect on the 
inhibitory activities against HDAC compared with the 
linker between zinc binding group and 1,3,4-
thiadiazole ring. To further validate the utility of this 
set of structures at the cellular level, the effect of the 
exposure of selected compounds was tested on the 
viability of MDA-MB-231 (breast cancer cell) and 
K562 (chronic myelogenousleukemia cell), A549 
(human lung cancer), PC3 (Prostate cancer cell lines). 
We evaluated compounds 5a, 5b, and 5e using MTT 
assay. The IC50 values were summarized in Table II.  
 
Scheme I 





Table I — HDAC activity of substituted 1,3,4-thiadiazole hydroxamates and carboxylates derivatives 
















































































Table I — HDAC activity of substituted 1,3,4-thiadiazole hydroxamates and carboxylates derivatives (Contd.) 




















































































Table II — Proliferative activities of representative compounds against various cancer cell lines 
S. No Compd IC50 value of 
HDAC(µM) 
MDA-MB-231 
IC50 value (µM) 
K562 
IC50 value (µM) 
A549 
IC50 value (µM) 
PC3 
IC50 value (µM) 
1 HA01 0.19± 0.04 19.43 23.59 >50 45.89 
2 HA02 0.27 ± 0. 05 35.13 32.57 23.56 >50 
3 HA05 0.31± 0.004 14.67 38.47 35.87 26.56 
4 SAHA 0.15±0.02 1.35 1.96 4.10 5.56 
 
Table III — Molecular docking studies of synthesized compounds 
S. No. Compd ID Docking Score HBD HBA Mol. Wt. CLOGP 
1 4a CA01 -23.2407 2 6 311.744 1.859 
2 4b CA02 -24.1379 3 7 293.298 0.952 
3 4c CA03 -35.3017 3 7 293.298 0.952 
4 4d CA04 -19.4404 2 6 291.326 1.229 
5 4e CA05 -21.5976 2 6 347.432 2.886 
6 4f CA06 -21.9883 2 6 277.299 1.984 
7 4g CA07 -21.6959 4 7 292.314 0.448 
8 4h CA08 -16.0321 2 9 322.297 1.089 
9 4i CA09 -49.5047 2 6 229.256 0.952 
10 4j CA10 -46.7130 2 6 243.283 0.653 
11 5a HA01 -81.9616 3 7 326.759 1.244 
12 5b HA02 -76.0022 4 8 308.313 0.337 
13 5c HA03 -74.1298 4 8 308.313 0.337 
14 5d HA04 -74.7134 3 7 306.24 0.614 
15 5e HA05 -75.3654 3 7 362.447 2.271 
16 5f HA06 -69.5264 3 7 292.314 0.579 
17 5g HA07 -66.3344 5 8 307.328 -0.167 
18 5h HA08 -62.274 3 10 337.311 0.474 
19 5i HA09 -74.7416 3 7 244.271 -0.418 
20 5j HA10 -72.0623 3 7 258.297 0.038 
 
Among these compounds, all of them could inhibit the 
cell proliferation effectively activity. In molecular 
docking, the reference binding mode of HDAC was 
predicted with docking protocol (PDB Code 1w22) 
and a docking score of −82.29 was found. The 
binding interaction shows H-bond with polar amino 
acid (Thr306) and p-p interaction with hydrophobic 
residues of His142. All the test compounds were 
further docked and their docking scores were 
predicted (Table III). For test compounds a common 
binding mode was observed, where binding site is 
comprised of His 143, His 180, His 142, Phe 152, Phe 
208 and Tyr 306 amino acid residues. log P values 
(045-1.85) for the test compounds were noted target 
compounds also shows mild to moderate similarity 
with respect to standard drug. 
 
Materials and Methods 
All the chemicals used were of laboratory grade 
and procured from Rankem Astron (India). and Sigma 
Aldrich. Melting point of synthesized compounds 
were performed in one end open capillary on VEEGO 
(VMP-PM) melting point apparatus. The purity of 
compound were performed by using pre-coated TLC 
plates and solvent systems. The TLC evaluated in UV 
chamber at 254 nm wave length and Iodine chamber. 
The FT-IR of synthesized compounds were performed 
on SIMADZU FT-IR 8400 by using KBr pellets.  
The 1H NMR (Nuclear Magnetic Resonance) and  
13C NMR of synthesized compounds were performed 
on BRUKER AVANCE-III 400 MHz FT-NMR 
instrument by using the DMSO/CDCl3 as solvent, 
TMS as internal standard. The signals are quoted as 
follows: s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; bs, broad singlet and are expressed in  
d ppm. Mass spectra (GC-MS) of synthesized 
compounds were performed on SHIMADZU QP2010. 
 
Docking 
Docking predicts the binding orientation and 
affinity of a ligand to a target. Software used for 
docking is FRED 2.0,Open Eye Scientific software.  
It is used to dock a large collection of molecules into 
the active site of a target protein.It determines the 




database file format from the file extension. mol. 
Subsequent screening is based on the crystal structure 
of HDAC( PDB code:1w22).Using a combination of 
various aspects such as, structure generation, shape 
alignment and flexible fitting, a ligand of interest is 
compared to bound ligands and its similarity to such 
both guides the nature of the applied algorithm and 
produces an accuracy estimate. Poses are analysed 
and selected from Discovery Studio Visualizer. Drug 
likeness is also calculated from the same. 
 
In vitro HDAC assay 
We performed assays according to the kit instruction 
(BML-AK501-0001 HDAC Colorimetric acitivity 
assay kit). HDAC came from HeLa cell nucleus 
extracts, mainly including HDAC1 and HDAC2. The 
tested compounds and the control drug SAHA 
(Figure 2, Figure 3 and Figure 4) were diluted to 
various concentrations. On the 96-well plate, HDAC  
(5 lL/well) were incubated at 37ºC with 10 lL of 
various concentrations of samples and 25 lL of 
substrate. After reacting for 30 min, Color de Lys 
Developer (50 lL/well) was added. Then, after 15 min 
the ultraviolet absorption of the wells was measured on 
a microtiter-plate reader at 405 nm. The inhibition rates 
were calculated from the ultraviolet absorption 
readings of inhibited wells related to those of control 
wells. Finally, the IC50 values were determined using a 
regression analysis of the concentration/inhibition. 
Thus, this assay has two step procedure. First, COLOR 
DE LYS substrate comprises an acetylated lysine side 
chain,is incubated with the sample containing HDAC 
activity.Deacetylation of the substrate sensitizes the 
substrate so that, in second step, mixing with the 
COLOE DE Lys developer causes an increase in 
yellow color intensity, and absorption at 405nm.  
 
MTT assay 
MDA-MB-231, K562, A549 and PC3 (Prostate 
cancer cell lines). were respectively cultured in 
RPMI1640 medium containing 10% FBS at 37ºC in 
5% CO2 humidified incubator. Cell proliferation  
was determined by the MTT (3- [4,5-dimethyl- 
2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide) 
assay. Briefly, cells were plated in a 96-well plate at 
10,000 cells per well, cultured for 4 h in complete 
 
 




Figure 3 — Common framework for SAHA with amino-acid 




growth medium, then treated with 2000, 400, 80, 16, 
3.2, 0.64 mg/mL of compounds for 48 h. 0.5% MTT 
solution was added to each well. After further 
incubation for 4 h, formazan formed from MTT was 
extracted by adding 200 lL DMSO and mixing for  
15 min. Optical density was read with anmicrotiter-




A strring mixture of benzoic acid (0.05 mol), 
N-amino-thiourea (0.05 mol) and POCl3 (13 mL) was 
heated at 75ºC for 0.5 h. After cooling down to RT, 
water (10 mL) was added. The reaction mixture was 
refluxed for 4 hr. After cooling, the mixture was 
basified to pH 8 by the drop-wise addition of 50% 
NaOH solution under strring. The precipitate was 
filtered and recrystallized from ethanol to yield the 
target compound 3a as a colorless crystal. Yield: 
60%, m.p. 213-215ºC; ESI-MS m/z: 212; 1H NMR 
(400 MHz, DMSO-d6): δ 10.30 (s, 1H, NH), 3.30-6.40 
(m, 4H, Ph-C2-C3-C5-C6).. 
Compounds 3b-j were synthesized following the 
procedure described above. 
4-(5-Amino-1,3,4-thiadiazol-2-yl)phenol, 3b: Yield: 
78%, m.p. 209-213ºC ESI-MS m/z (M+1) 195,  
1H NMR (400 MHz, DMSO-d6): δ 11.15 (s, 1H, 
1OH), 10.03 (s, 1H, NH), 4.70-6.31 (m, 4H, Ph-C2-
C3-C5-C6). 
2-(5-Amino-1,3,4-thiadiazol-2-yl)phenol, 3c: Yield: 
64%, m.p. 212-215ºC ESI-MS m/z (M+1): 195,  
1H NMR (400 MHz, DMSO-d6): δ 10.35 (s, 1H, NH), 
3.70-5.31 (m, 4H, Ph-C2-C3-C5-C6). 
5-Benzyl-1,3,4-thiadiazol-2-amine, 3d: Yield: 
75%, m.p. 211-215ºC ESI-MS m/z (M-1): 190; 
1H NMR (400 MHz, DMSO-d6): δ 11.01 (s, 1H, 
1OH), 10.20 (s, 1H, NH), 4.70-6.90 (m, 5H, Ph-C2-
C3- C4-C5-C6). 
5-(1-(4-Isopropylphenyl)ethyl)-1,3,4-thiadiazol-
2-amine, 3e: Yield: 80%, m.p. 205-208ºC; ESI-MS 
m/z (M-2) 245; 1H NMR (400 MHz DMSO-d6):  
δ 10.39 (s, 1H, NH), 3.70-6.12 (m, 4H, Ph-C2-C3-C5-
C6), 2.50-3.30 (s, 4H, CH2-CH2). 
5-Phenyl-1,3,4-thiadiazol-2-amine, 3f: Yield: 
68%, m.p. 207-209ºC ESI-MS m/z (M-1) 176; 
1H NMR (400 MHz DMSO-d6): δ 10.39 (s, 1H, NH), 
4.70-7.59 (m, 5H, Ph-C2-C3-C4-C5-C6). 
2-Amino-5-substituted-1,3,4-thiadiazole, 3g: Yield: 
69%, m.p. 209-211ºC ESI-MS m/z: 192; 1H NMR 
(400 MHz DMSO-d6): δ 11.23-11.59 (d, 2H, NH), 
4.70-7.52 (m, 4H, Ph-C2-C3-C5-C6). 
5-(4-Nitrophenyl)-1,3,4-thiadiazol-2-amine, 3h: 
Yield: 49%, m.p. 206-209ºC ESI-MS m/z (M-1): 221; 
 
 
Figure 4 — Docking of the molecule with crystal structure having Pdb Code: 1w22 
 




1H NMR (400 MHz DMSO-d6): δ 10.45 (s, 1H, NH), 
4.10-6.92 (m, 4H, Ph-C2-C3-C5-C6). 
5-Ethyl-1,3,4-thiadiazol-2-amine, 3i: Yield: 70%, 
m.p. 202-205ºC ESI-MS m/z (M-1) 128; 1H NMR 
(400 MHz DMSO-d6): δ 10.45 (s, 1H, NH), 2.50-3.32 
(s, 4H, CH2-CH2). 
5-Propyl-1,3,4-thiadiazol-2-amine, 3j: Yield: 69%, 
m.p. 210-213ºC ESI-MS m/z (M-1) 142; 1H NMR 
(400 MHz DMSO-d6): δ 10.10 (s, 1H, NH), 2.50-4.91 
(m, 4H, CH2-CH2,CH3). 
4-Oxo-((5-phenyl-1,3,4-thiadiazole-2-yl)) amino) 
butanoic acid, 4a: Succinic anhydride (0.02mol) was 
added to a solution of thiadiazole in a hot acetonitrile 
(150 mL). The solution was heated for 1 hr under 
reflux. After cooling, the precipitate product was 
collected. Recrystallization is carried out using alcohol 
to give 4a as white solid. Yield: 56%, m.p. 250-253ºC; 
ESI-MS m/z (M+1)312; 1H NMR (400 MHz, DMSO-
d6): δ 12.10-12.33 (m, 2H, 2OH), 10.90 (s, 1H, NH), 
6.69-7.42 (m, 4H, Ph-C2-C3-C5-C6), 2.40-2.62 (d, 4H, 
CH2-CH2); 13C NMR (400 MHz, DMSO-d6): δ 177.3, 
176.6 (C=O), 166.03 (Thiadiazole-C2), 153 
(Thiadiazole-C5), 134 (Ph-C4), 129.44 (Ph-C3-C5), 
128.85 (Ph-C2-C6), 30.70, 32.30 (CH2-CH2). 
Compounds 4b-j were synthesized following the 
procedure described above. 
4-(5-(4-Hydroxyphenyl)-1,3,4-thiadiazol-2-
ylamino)-4-oxobutanoic acid, 4b: Yield: 55%, m.p. 
248-250ºC; ESI-MS m/z: (M+1) 295; 1H NMR (400 
MHz, DMSO-d6): δ 11.30-1.99 (m, 2H, 2OH), 10.59 
(s, 1H, NH), 6.70-7.31 (m, 4H, Ph-C2-C3-C5-C6), 2.41-
2.59 (d, 4H, CH2-CH2); 13C NMR (400 MHz, DMSO-
d6): δ 177.30, 175.6 (C=O), 152.30 (Thiadiazole-C5), 
158.50 (Ph-C4), 126.10 (Ph-C1), 116.40 (Ph-C3-C5), 
128 (Ph-C2-C6), 30.7- 32.30 (CH2-CH2). 
4-(5-(2-Hydroxyphenyl)-1,3,4-thiadiazol-2-
ylamino)-4-oxobutanoic acid, 4c: Yield: 62%, m.p. 
254-258ºC; ESI-MS m/z (M+1) 295; 1H NMR (400 
MHz, DMSO-d6): δ 12.33-12.46 (m, 2H, 2OH), 
10.093 (s, 1H, NH), 6.89-7.76 (m, 4H, Ph-C2-C3-C5-
C6), 3.357 (s, 4H, CH2-CH2); 13C NMR (400 MHz, 
DMSO-d6): δ 177.3, 175.6 (C=O), 173.70 
(Thiadiazole-C2), 155 (Thiadiazole-C5), 136.1 (Ph-
C4), 135.09 (Ph-C1), 129 (Ph-C3-C5), 128.92 (Ph-C2-
C6), 30.70- 32.50 (CH2-CH2). 
4-(5-Benzyl-1,3,4-thiadiazol-2-ylamino)-4-
oxobutanoic acid, 4d: Yield: 65%, m.p. 238-241ºC; 
ESI-MS m/z (M-1) 291; 1H NMR (400 MHz, DMSO-
d6): δ 12.90 (s, 1H, 1OH), 10.80 (s, 1H, NH), 7.06-
7.16 (m, 5H, Ph-C2-C3-C4-C5-C6), 2.30-2.50  
(d, 4H, CH2-CH2); 13C NMR (400 MHz, DMSO-d6):  
δ 177.3, 173.7 (C=O), 161.00 (Thiadiazole-C2), 
152.80 (Thiadiazole-C5), 136.1 (Ph-C4), 129.15  
(Ph-C1), 128.70 (Ph-C3-C5), 125.80 (Ph-C2-C6), 
30.70- 32.90 (CH2-CH2), 37.60 (CH2). 
4-(5-(1-(4-Isopropylphenyl)ethyl)-1,3,4-
thiadiazol-2-ylamino)-4-oxobutanoic acid, 4e: 
Yield: 76%, m.p. 238-240ºC; ESI-MS m/z: 277; 
1H NMR (400 MHz, DMSO-d6): δ 11.45 (s, 1H, 
1OH), 11.03 (s, 1H, NH), 6.65-7.10 (m, 5H, Ph-C2-
C3-C4-C5-C6), 2.40-2.60 (m, 4H, CH2-CH2); 13C NMR 
(400 MHz, DMSO-d6) δ 175.3, 172.3(C=O),  
163.00 (Thiadiazole-C2), 151 (Thiadiazole-C5), 134.1  
(Ph-C4), 126.15 (Ph-C1), 125.70 (Ph-C3-C5), 123.80 
(Ph-C2-C6), 24.00- 39.90 (m, 15H, CH2-CH2). 
4-Oxo-4-(5-phenyl-1,3,4-thiadiazol-2-ylamino) 
butanoic acid, 4f: Yield: 53%, m.p. 249-253ºC; ESI-
MS m/z (M+1) 293; 1H NMR (400 MHz, DMSO-d6): 
δ 11.71 (s, 1H, 1OH), 10.50 (s, 1H, NH), 7.10-7.56 
(m, 5H, Ph-C2-C3-C4-C5-C6), 2.10-2.61 (m, 4H, CH2-
CH2); 13C NMR (400 MHz, DMSO-d6): δ 177.3, 
175.6 (C=O), 173.70 (Thiadiazole-C2), 152.30 
(Thiadiazole-C5), 129.30 (Ph-C4), 127.09 (Ph-C1), 133 
(Ph-C3-C5), (Ph-C2-C6), 30.70- 32.50 (CH2-CH2). 
4-(5-(4-Aminophenyl)-1,3,4-thiadiazol-2-ylamino)- 
4-oxobutanoic acid, 4g: Yield: 59%, m.p. 238-241ºC; 
ESI-MS m/z: (M+1) 323; 1H NMR (400 MHz, 
DMSO-d6): δ 12.21 (s, 1H, 1OH), 10.10 (s, 1H, NH), 
7.00-7.50 (m, 4H, Ph-C2-C3-C5-C6), 2.40-2.61 (d, 4H, 
CH2-CH2); 13C NMR (400 MHz, DMSO-d6):  
δ 177.30, (C=O), 152 (Thiadiazole-C5), 136.1 (Ph-
C4), 135.09 (Ph-C1), 128.30 (Ph-C3-C5), 116 (Ph-C2-
C6), 30.70- 32.30 (CH2-CH2). 
4-(5-(4-Nitrophenyl)-1,3,4-thiadiazol-2-ylamino)- 
4-oxobutanoic acid, 4h: Yield: 42%, m.p. 242-
245ºC; ESI-MS m/z: 322; 1H NMR (400 MHz, 
DMSO-d6): δ 12.10 (s, 1H, 1OH), 10.80 (s, 1H, NH), 
7.15-8.23 (m, 4H, Ph-C2-C3-C5-C6), 2.31-2.61 (d, 4H, 
CH2-CH2); 13C NMR (400 MHz, DMSO-d6): δ 177.3, 
170.6 (C=O), 166.03 (Thiadiazole-C2), 152.30 
(Thiadiazole-C5), 148.40 (Ph-C1), 128.31 (Ph-C3-C5), 
116.50 (Ph-C2-C6), 30.70-32.30 (CH2-CH2). 
4-(5-Ethyl-1,3,4-thiadiazol-2-ylamino)-4-
oxobutanoic acid, 4i: Yield: 60%, m.p. 218-220ºC 
ESI-MS m/z (M+1): 230; 1H NMR (400 MHz, 
DMSO-d6): δ 12.20 (m, 2H, 2OH), 10.10 (s, 1H, NH), 
2.10-2.74 (m, CH2-CH2); 13C NMR (400 MHz, 
DMSO-d6): δ 174.3, 170.6 (C=O), 168.03 
(Thiadiazole-C2), 150.30 (Thiadiazole-C5), 31.70-
34.30 (CH2-CH2), 16.70-21.30 CH2-CH2). 





butanoic acid, 4j: Yield: 65%, m.p. 224-229ºC; ESI-
MS m/z: 243; 1H NMR (400 MHz, DMSO-d6): δ 
11.45 (s, 1H, 1OH), 10.79 (s, 1H, NH), 1.19-4.87 (m, 
11H, CH2-CH2). CH2-CH2); 13C NMR (400 MHz, 
DMSO-d6):δ 175.3, 172.4 (C=O), 170.03 
(Thiadiazole-C2), 155.30 (Thiadiazole-C5), 17.70-
35.30 (m, 12C, CH2-CH2). 
N1-(5-(4-Chlorophenyl)-1,3,4-thiadiazol-2-yl)-N4- 
hydroxysuccinamide, 5a 
To a -20ºC cooled solution of acid derivative 
(0.07mole) and N-methylmorpholine (0.014mole) in 
anhydrous N,N-dimethylformamide (15 mL) was 
added ClCOOBu-i (isobutyl chloroformate), and the 
mixture was stirred for 0.5h. The solid was filtered 
out and filtrate was added to freshly prepared NH2OK 
in methanol (5 mL, 1.54mol/L).The resulting mixture 
was stirred at RT overnight, then was filtered and the 
residue was washed with water to give crude product. 
Recrystallization is carried out using ethanol to give 
5a as white solid. Yield: 52%, m.p. 207-209ºC; 
1H NMR (400 MHz, CDCl3-d6): δ 12.50 (s, 1H, OH), 
11.10 (s, 1H, NH), 8.0 (s, 1H, NH), 7.42 (d, 2H, Ph-
C2-C6), 7.33 (d, 2H, Ph-C3-C5), 2.48-32.451 (CH2-
CH2); 13C NMR (400 MHz, DMSO-d6): δ 175.47, 
173.27 (C=O), 170.00 (Thiadiazole-C2), 152 
(Thiadiazole-C5), 134 (Ph-C4), 129.47 (Ph-C1), 128.95 
(Ph-C3-C5), 126.97 (Ph-C2-C6), 28.00- 31.65 (CH2-
CH2). 
Compounds 5b-j were synthesized following the 
procedure described above. 
N1-Hydroxy-N4-(5-(4-hydroxyphenyl)-1,3,4-
thiadiazol-2-yl)succinamide, 5b: Yield: 51%, m.p. 
207-209ºC; ESI-MS m/z (M+1):309; 1H NMR (400 
MHz, CDCl3-d6): δ 12.30 (s, 1H, OH), 10.90 (s, 1H, 
NH), 8.010 (s, 1H, NH), 7.314 (d, 2H, Ph-C2-C6), 
6.79 (d, 2H, Ph-C3-C5), 2.461-2.00 (m, 2H, CH2); 
13C NMR (400 MHz, DMSO-d6) δ 172.47, 170.27 
(C=O), 163.00 (Thiadiazole-C2), 158 (Thiadiazole-
C5), 137 (Ph-C4), 128.77 (Ph-C1), 128.73 (Ph-C3-C5), 
126.97 (Ph-C2-C6), 27.95- 29.65 (CH2-CH2). 
N1-Hydroxy-N4-(5-(2-hydroxyphenyl)-1,3,4-
thiadiazol-2-yl)succinamide, 5c: Yield: 56%, m.p. 
207-209ºC; ESI-MS m/z (M-1) 307.9; 1H NMR  
(400 MHz, CDCl3-d6): δ 12.10 (s, 1H, OH), 10.20 (s, 
1H, NH), 8.10 (s, 1H, NH), 6.99 (d, 2H, Ph-C2-C6), 
6.29 (d, 2H, Ph-C3-C5), 2.461-2.00 (m, 2H, CH2); 
13C NMR (400 MHz, DMSO-d6): δ 175.00, 173.7 
(C=O), 170.00 (Thiadiazole-C2), 158 (Thiadiazole-
C5), 130 (Ph-C4), 126.77 (Ph-C1), 123.73 (Ph-C3-C5), 
121.97 (Ph-C2-C6), 31.00- 28.00 (CH2-CH2). 
N1-(5-Benzyl-1,3,4-thiadiazol-2-yl)-N4-
hydroxysuccinamide, 5d: Yield: 61%, m.p. 207-209° 
C ESI-MS m/z: 1H NMR (400 MHz, CDCl3-d6):  
δ 13.10 (s, 1H, OH), 11.80 (s, 1H, NH), 8.010 (s, 1H, 
NH), 7.42 (d, 2H, Ph-C2-C6), 7.14 (d, 2H,  
Ph-C3-C5), 3.810 (s, 2H, CH2), 2.481 (m, 2H, CH2); 
13C NMR (400 MHz, DMSO-d6): δ 173.70, 170.60 
(C=O), 161.00 (Thiadiazole-C2), 152 (Thiadiazole-
C5), 136 (Ph-C4), 129.15 (Ph-C1), 129.90 (Ph-C3-C5), 
128.97 (Ph-C2-C6), 28.00- 31.60 (CH2-CH2), 37.80 
(CH2). 
N1-Hydroxy-N4-(5-phenyl-1,3,4-thiadiazol-2-yl) 
succinamide, 5e: Yield: 61%, m.p. 207-209ºC; ESI-
MS m/z (M-1) 292; 1H NMR (400 MHz, CDCl3-d6): δ 
12.63 (s, 1H, OH), 11.72 (s, 1H, NH), 8.9 (s, 1H, 
NH), 7.89 (d, 2H, Ph-C2-C6), 7.51 (d, 2H, Ph-C3-C5), 
3.07-3.13 (m, 2H, CH2), 2.83-2.93 (m, 2H, CH2); 
13C NMR (400 MHz, DMSO-d6): δ 173.70 (C=O), 
170.60 (Thiadiazole-C2), 152.30 (Thiadiazole-C5), 
133 (Ph-C4), 129.35 (Ph-C1), 128.73 (Ph-C3-C5), 
127.51 (Ph-C2-C6), 28.00- 31.00 (CH2-CH2), 34.5 
CH3. 
N1-(5-(4-Aminophenyl)-1,3,4-thiadiazol-2-yl)-
N4-hydroxysuccinamide, 5f: Yield: 52%, m.p. 207-
209ºC; ESI-MS m/z: (M+1) 308; 1H NMR (400 MHz, 
CDCl3-d6) δ 12.5 (s, 1H, OH), 10.90 (s, 1H, NH), 
8.010 (s, 1H, NH), 7.23 (d, 2H, Ph-C2-C6), 6.51 (d, 
2H, Ph-C3-C5), 4.00 (Ar-NH2) 2.46-2.50 (m, 2H, 
CH2); 13C NMR (400 MHz, DMSO-d6): δ 176.00, 
173.70 (C=O), 170.60 (Thiadiazole-C2), 152.30 
(Thiadiazole-C5), 133 (Ph-C4), 129.35 (Ph-C1), 128.73 
(Ph-C3-C5), 127.51 (Ph-C2-C6), 28.00- 31.00  
(CH2-CH2). 
N1-(5-(4-Aminophenyl)-1,3,4-thiadiazol-2-yl)-
N4-hydroxysuccinamide, 5g: Yield: 67%, m.p. 207-
209ºC; ESI-MS m/z (M+1) 308; 1H NMR (400 MHz, 
CDCl3-d6): δ 12.10 (s, 1H, OH), 8.2 (s, 1H, NH), 4.1 
(s, 1H, NH2), 6.52 (d, 2H, Ph-C2-C6), 7.23 (d, 2H, Ph-
C3-C5); 13C NMR (400 MHz, DMSO-d6): δ 175.00, 
173.70 (C=O), 170.00 (Thiadiazole-C2), 152.30 
(Thiadiazole-C5), 148 (Ph-C4), 128.30 (Ph-C1), 123.30 
(Ph-C3-C5), 116.80 (Ph-C2-C6), 28.00- 31.60 (CH2-
CH2). 
N1-Hydroxy-N4-(5-(4-nitrophenyl)-1,3,4-thiadiazol- 
2-yl)succinamide, 5h: Yield: 60%, m.p. 204-206ºC; 
ESI-MS m/z: 337; 1H NMR (400 MHz, CDCl3-d6):  
δ 12.50 (s, 1H, OH), 10.10 (s, 1H, NH), 7.56 (d, 2H, 
CH2-CH2), 7.74 (d, 2H, Ph-C2-C6), 2.48-2.80 (CH2-
CH2); 13C NMR (400 MHz, DMSO-d6): δ 175.00, 




173.70 (C=O), 170.00 (Thiadiazole-C2), 152.30 
(Thiadiazole-C5), 148 (Ph-C4), 128.45 (Ph-C1), 128.40 
(Ph-C3-C5), 121.60 (Ph-C2-C6), 28.00- 31.00  
(CH2-CH2). 
N1-(5-Ethyl-1,3,4-thiadiazol-2-yl)-N4-hydro-
xysuccinamide, 5i: Yield: 60%, m.p. 202-205ºC; 
ESI-MS m/z:244; 1H NMR (400 MHz, CDCl3-d6): δ 
10.50 (s, 1H, OH), 9.56 (s, 1H, NH), 8.0 (s, 1H, NH), 
2.46-2.59 (CH2-CH2), 2.00 (CH2); 13C NMR (400 
MHz, DMSO-d6): δ 175.00, 173.7 (C=O), 170.00 
(Thiadiazole-C2), 152 (Thiadiazole-C5), 31.00- 28.00 
(m, 8H, CH2-CH2). 
N1-Hydroxy-N4-(5-propyl-1,3,4-thiadiazol-2-yl) 
succinamide, 5j: Yield: 60%, m.p. 199-202ºC; ESI-
MS m/z: 258.03; 1H NMR (400 MHz, CDCl3-d6): δ 
11.10 (s, 1H, OH), 10.08 (s, 1H, NH), 8.2  
(s, 1H, NH), 2.48-2.59 (CH2-CH2), 2.00 (CH3), 2.20 
(CH2); 13C NMR (400 MHz, DMSO-d6): δ 173.7, 
170.0 (C=O), 165 (Thiadiazole-C2), 150 (Thiadiazole-
C5), 31.00- 28.00 (m, 8H, CH2-CH2), 30.5 (CH3). 
 
Conclusions 
In conclusion, we have developed various 
hydroxamic acid and carboxylic acid derivatives 
through cyclization and condensation approach 
through various aliphatic and aromatic substituents. 
The synthesis, computational studies and their 
evaluation for anticancer activity of new inhibitors are 
been carried out.The target compounds were 
successfully synthesized and well characterized by 
molecular docking studies revealed good binding 
interactions of target molecules. The target 
compounds also showed mild to moderate similarity 
with respect to standard drug. The pharmacokinetic 
and toxicity corroborate with standard compound and 
suggests its potential being drug-like candidates. 
However, further optimization might be beneficial  
in the future research and development of the  
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